VeraDermics develops first-in-class therapeutics utilizing novel drug delivery mechanisms to provide pain-free treatments for prevalent skin conditions, including common warts and pattern hair loss. The company's lead product candidate, VDPHL, offers a once-daily, non-hormonal oral solution specifically targeting androgenetic alopecia.
Funding
$113.1M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current treatments for common warts and pattern hair loss often involve painful or inconvenient topical applications and may have limited efficacy. Existing solutions can also present challenges in terms of patient compliance and tolerability, leading to suboptimal outcomes.
Solution
VeraDermics is developing novel, first-in-class therapeutics utilizing innovative drug delivery mechanisms to provide pain-free treatments for prevalent skin conditions. Their pipeline focuses on addressing unmet needs in dermatology with a portfolio of product candidates targeting conditions such as androgenetic alopecia (pattern hair loss), common warts (verruca vulgaris), alopecia areata, molluscum contagiosum, and atopic dermatitis. The company's lead product candidate, VDPHL, is a once-daily, non-hormonal oral solution specifically targeting androgenetic alopecia, offering a more convenient and potentially more effective treatment option.
Target Audience
The primary target audience includes individuals suffering from common warts and androgenetic alopecia (pattern hair loss), as well as dermatologists seeking more effective and convenient treatment options for their patients.
Features
- VDPHL: A once-daily, non-hormonal oral solution for androgenetic alopecia
- Focus on pain-free drug delivery mechanisms
- Pipeline of five dermatological candidates with potential first-in-class market opportunities
- Therapeutics address real-world patient needs and solve treatment challenges in under-innovated markets